Format

Send to

Choose Destination
Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12632. Epub 2016 Dec 28.

Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.

Author information

1
Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2
Division of Medical Oncology, Duke University School of Medicine, Durham, NC, USA.
3
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4
Department of Emergency Medicine and Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6
Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7
Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
8
Department of Transplant Surgery, Houston Methodist Hospital, Houston, TX, USA.
9
Division of Cardiology, Interventional Cardiology, Loma Linda University Health, Loma Linda, CA, USA.

Abstract

BACKGROUND:

BK polyomavirus (BKPyV) infections are known indicators of immune suppression in hematopoietic stem cell transplant (HSCT) recipients; they can lead to hemorrhagic cystitis, ureteral stenosis, renal dysfunction, and prolonged hospital stays. In this study, we determined transplant-associated variables and immune parameters that can predict for the risk of BKPyV viruria. We hypothesized that BKPyV infection is a marker of poor immune recovery.

METHODS:

We analyzed all engrafted patients undergoing first allogeneic HSCT at MD Anderson Cancer Center in Houston between January 2004 and December 2012. We evaluated their immune parameters and their transplant-associated factors. BKPyV positivity was defined as BKPyV detection in urine by polymerase chain reaction testing. Cox proportional hazards model, as well as competing risk analysis method using subdistribution hazard models with death as competing risk, were applied to assess risk of BKPyV viruria.

RESULTS:

We identified a total of 2477 patients with a median age of 52 years. BKPyV viruria was manifest in 25% (n=629) of the patients. The median time from transplantation to BKPyV viruria development was 42 days among the patients who had BKPyV viruria. On multivariate analysis, tumor type, acute GVHD, chronic GVHD, myeloablative conditioning regimen, cord blood as the graft source, CD3+ , CD4+ , CD8+ , CD56+ , NK counts, and low platelet count were shown to be significantly associated with BKPyV infection. These finding were further confirmed when models incorporating the competing risk of death yielded similar findings.

CONCLUSION:

In this study, we report significant associations between BKPyV reactivation following allogeneic HSCT and suppressed immune variables. In addition, this study provides valuable information on the immune status of HSCT recipients as a predictor of BKPyV infections that may in turn help us formulate plans for more effective prevention and treatment of this infection.

KEYWORDS:

BK virus; T-cell suppression; allogeneic stem cell transplant; immune suppression

PMID:
27862740
DOI:
10.1111/tid.12632
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center